Key Details
Price
$45.51Annual ROE
-83.65%Beta
0.79Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI. Jessica Fye - JP Morgan Dae Gon Ha - Stifel Brian Skorney - Baird David Lebowitz - Citi Thomas Yip - H.C.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.92 per share a year ago.
Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC.
FAQ
- What is the primary business of Mirum Pharmaceuticals?
- What is the ticker symbol for Mirum Pharmaceuticals?
- Does Mirum Pharmaceuticals pay dividends?
- What sector is Mirum Pharmaceuticals in?
- What industry is Mirum Pharmaceuticals in?
- What country is Mirum Pharmaceuticals based in?
- When did Mirum Pharmaceuticals go public?
- Is Mirum Pharmaceuticals in the S&P 500?
- Is Mirum Pharmaceuticals in the NASDAQ 100?
- Is Mirum Pharmaceuticals in the Dow Jones?
- When was Mirum Pharmaceuticals's last earnings report?
- When does Mirum Pharmaceuticals report earnings?
- Should I buy Mirum Pharmaceuticals stock now?